Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurol Sci ; 306(1-2): 115-20, 2011 Jul 15.
Article in English | MEDLINE | ID: mdl-21501850

ABSTRACT

We studied the effects of fasudil, a selective Rho-kinase inhibitor, on experimental autoimmune neuritis (EAN). Continuous parenteral administration of fasudil prevented the development of EAN induced by P0 peptide 180-199 in Lewis rats while it also reduced EAN severity when administered after disease onset. Immunohistochemical examination disclosed a marked decrease in the amount of inflammatory cell infiltration and attenuation of demyelination and axonal degeneration. Specific proliferation of lymphocytes from fasudil-treated rats in response to P0 peptide was significantly reduced as compared with those from phosphate-buffered saline (PBS)-treated rats. Fasudil treatment was associated with a significant reduction in secretion of IFN-γ; by contrast, secretion of IL-4 was almost the same in the fasudil- and PBS-treated groups. As a result, the IFN-γ/IL-4 ratio in the supernatant was significantly deceased in fasudil-treated rats compared with PBS-treated ones. Therefore, our results indicate a beneficial effect of selective blockade of Rho-kinase in animals with autoimmune inflammation of the peripheral nerves, and may provide a rationale for the selective blockade of Rho-kinase as a new therapy for Guillain-Barré syndrome.


Subject(s)
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives , Neuritis, Autoimmune, Experimental/drug therapy , Neuritis, Autoimmune, Experimental/prevention & control , Protein Kinase Inhibitors/administration & dosage , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/administration & dosage , Animals , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/physiology , Carrier Proteins/metabolism , Cell Proliferation/drug effects , Cytokines/metabolism , Disease Models, Animal , Drug Administration Schedule , Drug Delivery Systems , Lymph Nodes/metabolism , Male , Myelin P0 Protein/adverse effects , Neuritis, Autoimmune, Experimental/chemically induced , Neuritis, Autoimmune, Experimental/pathology , Neutrophil Infiltration/drug effects , Phosphoproteins/metabolism , Rats , Rats, Inbred Lew , Sodium-Hydrogen Exchangers , rho-Associated Kinases/antagonists & inhibitors , rho-Associated Kinases/metabolism
2.
J Neurol Sci ; 255(1-2): 1-6, 2007 Apr 15.
Article in English | MEDLINE | ID: mdl-17306302

ABSTRACT

To explore subclinical central nervous system (CNS) involvement in chronic inflammatory demyelinating polyneuropathy (CIDP), we recorded somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs) using transcranial magnetic stimulation, to measure central sensory conduction time (CSCT) and central motor conduction time (CMCT) and examined brain and spinal cord MRI in patients with probable CIDP based on the American Academy of Neurology AIDS Task Force criteria. Eighteen patients with probable CIDP (12 males and 6 females; mean age at examination+/-SD, 45.8+/-17.0 years; range, 17-72) were included in the study. Of the 13 patients who underwent SEPs, one had prolonged CSCT (8%) and of the 13 who underwent MEPs, four had abnormal CMCT (31%). Cranial MRI revealed five of 18 patients had abnormal scans, only one of which showed multiple ovoid periventricular lesions suggestive of demyelination while none showed any intramedullary lesion on spinal cord MRI. Thus, 6 of the 18 patients were considered to have subclinical demyelinative CNS involvement which had lower disability on Global Neurological Disability Score (GNDS) (p=0.0061), a male preponderance (0.0537) and a larger compound muscle action potential (CMAP) amplitude in the median nerve (p=0.005) than those without. The decrease of GNDS with immunologic therapies was nearly significant in the former (p=0.0556) but not in the latter. The results of the present study suggest that subclinical CNS involvement in CIDP is not uncommon in Japanese patients and that CIDP with subclinical CNS involvement is more demyelinative thus responsive to immunotherapies while those without have more axonal damage and less responsive to immunotherapies.


Subject(s)
Central Nervous System/physiopathology , Demyelinating Autoimmune Diseases, CNS/diagnosis , Demyelinating Autoimmune Diseases, CNS/physiopathology , Peripheral Nervous System/physiopathology , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/diagnosis , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/physiopathology , Adolescent , Adult , Aged , Brain/drug effects , Brain/pathology , Brain/physiopathology , Central Nervous System/drug effects , Central Nervous System/immunology , Demyelinating Autoimmune Diseases, CNS/drug therapy , Drug Resistance/immunology , Electrodiagnosis , Evoked Potentials, Motor/physiology , Evoked Potentials, Somatosensory/physiology , Humans , Immunotherapy/methods , Magnetic Resonance Imaging , Middle Aged , Neural Conduction , Peripheral Nervous System/drug effects , Peripheral Nervous System/immunology , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/drug therapy , Spinal Cord/drug effects , Spinal Cord/pathology , Spinal Cord/physiopathology , Transcranial Magnetic Stimulation , Treatment Outcome , Wallerian Degeneration/drug therapy , Wallerian Degeneration/immunology , Wallerian Degeneration/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...